Weembrace

Weembrace is the UK arm of the Weembrace Group, a healthcare

company focused on improving access to high-quality, affordable oncology therapies

and supportive care. Our portfolio spans small-molecule oncology medicines

alongside evidence-based onco-nutrition and onco-cosmeceutical solutions, enabling

comprehensive support across the cancer pathway—from treatment to recovery. 

Backed by 35+ years in pharmaceutical manufacturing, supply, and hospital

distribution, Weembrace operates a controlled, quality-driven network serving

government and private providers. Our partners’ facilities are WHO-GMP aligned

and operate under robust SOPs covering sourcing, production, packaging, and

logistics. We prioritize regulatory diligence and timely product registrations, working

with local experts to ensure ethical commercialization and consistent quality in each

market. 

Weembrace maintains full regulatory compliance across states and

supports large public-sector and institutional demand with dependable service levels.

Internationally, we collaborate across the Middle East, Africa, Europe, and the CIS to

strengthen access to essential oncology care. 

At WHX Dubai, Weembrace Karevia is seeking distribution partners, hospital and

pharmacy group buyers, and health-system stakeholders interested in reliable

oncology supply, co-development of formulations, and market-appropriate nutrition

and dermal support for oncology patients. Our goal is consistent: safer, dependable

access to cancer care products at sustainable prices.